MXM (3-MeO-2'-Oxo-PCM) is the N-methyl homologue of methoxetamine; replacing the ethyl with a methyl lowers potency roughly 2- to 3-fold but shortens the high to about three hours. Forum experiments suggest oral administration is far more efficient than insufflation, likely due to low nasal absorption; 50-75 mg oral produces warm, serene dissociation and mild empathogenic warmth, while the same amount intranasally may do little. Users describe a 'ketamine-lite' float with MXE-style emotional openness, but with faster tolerance and heavier compulsion to redose. Pharmacological screens (rat brain synaptosome & PDSP panels) show high-micromolar NMDA antagonism and mid-micromolar SERT inhibition, with negligible ΞΌ-opioid activity. Because bladder and renal fibrosis seen with chronic MXE are thought to be metabolite-linked, MXM's safety profile is unknownβurotoxicity precautions (hydration, 2-week breaks) are advised.
